TY - JOUR T1 - Review: ACE inhibitors delay microalbuminuria in diabetes without nephropathy and reduce mortality in diabetic nephropathy JF - Evidence Based Medicine JO - Evid Based Med SP - 144 LP - 144 DO - 10.1136/ebm.11.5.144 VL - 11 IS - 5 A2 - , Y1 - 2006/10/01 UR - http://ebm.bmj.com/content/11/5/144.abstract N2 - Strippoli GF, Craig MC, Schena FP, et al. Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression. J Am Soc Nephrol 2006;17:S153–5.OpenUrlAbstract/FREE Full Text 
 
 Q Do antihypertensive agents prevent onset of microalbuminuria in patients with diabetes without nephropathy and delay progression in patients with diabetic nephropathy? Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★☆ Nephrology ★★★★★★☆ Cardiology ★★★★★★☆ Endocrine ★★★★★☆☆ Data sources: Medline (1966 to September 2003), EMBASE/Excerpta Medica (1988 to September 2003), Cochrane Central Register of Controlled Trials (2004), reference lists, and authors in the field. Study selection and assessment: randomised controlled trials (RCTs) in any language comparing an antihypertensive agent with another antihypertensive agent or placebo in diabetic patients with and without nephropathy. 16 RCTs (n = 8570) in diabetic patients without nephropathy and 43 RCTs (n = 7545) in diabetic patients with nephropathy met the selection criteria. Quality assessment of individual studies was based on allocation concealment, intention to treat analysis, loss to follow up, and blinding. Outcomes: onset of microalbuminuria, all cause mortality, end stage renal disease … ER -